大成生化科技(00809.HK)年度淨虧擴大至24.3億港元
格隆匯 4 月 1日丨大成生化科技(00809.HK)發佈截至2020年12月31日止年度全年業績公吿,於本年度,由於新型冠狀病毒肺炎的爆發導致經濟增長放緩,而經營環境長期充滿挑戰,致使集團的經營現金流緊張,集團的大部分生產設施因此暫停營運,銷量因而大幅下降。集團於本年度的綜合收益大幅減少81.4%至約8.489億港元。本年度的毛利減少約63.6%至約7410萬港元。公司擁有人應占虧損24.299億港元,同比擴大127.6%。基本每股虧損28.6港仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.